Emerging candidate biomarkers for Parkinson's disease: A review

Aging and Disease

Volumn 5, Issue 1, 2014, Pages 27-34

  Saracchi, Enrico ^a   Fermi, Silvia ^b   Brighina, Laura ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Azienda Ospedaliera di Lodi   (Italy)

Author keywords

Biomarkers; DJ 1; Parkinson's disease; Premotor; Proteomic; synuclein

Indexed keywords

EID: 84899907925     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14366/AD.2014.050027     Document Type: Review

References (50)

1. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K and Parkinson Study Group (2004). Levodopa and the progression of Parkinson's disease. N Engl J Med, 351: 2498-2508
2. Wu Y, Le W and Jankovic J (2011). Preclinical Biomarkers of Parkinson Disease. Arch Neurol, 68: 22-30
3. Lama M Chahine and Matthew B (2011). Stern Diagnostic markers for Parkinson's disease. Curr Opin Neurol, 24: 309-317
4. Vogt T, Kramer K, Gartenschlaeger M and Schreckenberger M (2011). Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating. Parkinsonism Relat Disord, 17: 459-463
5. Berg D, Siefker C, Ruprecht-Dörfler P and Becker G (2001). Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology, 9: 56:13-17
6. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J and Allsop D (2003). Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J, 17: 1945-1947
7. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M and Zhang J (2011). Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain, 134: e178
8. Gorostidi A, Bergareche A, Ruiz-Martínez J, Martí-Massó JF, Cruz M, Varghese S, Qureshi MM, Alzahmi F, Al-Hayani A, López de Munáin A and El-Agnaf OM (2012). Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One, 7: e52312
9. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG and Allsop D (2006). Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease FASEB J, 20: 419-425
10. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D and Allsop D (2011). Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease FASEB J, 25: 4127-4137
11. Brighina L, Prigione A, Begni B, Galbussera A, Andreoni S, Piolti R and Ferrarese C (2010). Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiol Aging, 31: 884-885
12. Prigione A, Piazza F, Brighina L, Begni B, Galbussera A, Difrancesco JC, Andreoni S, Piolti R, and Ferrarese C (2010). Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease. Neurosci Lett, 477: 6-10
13. Monahan AJ, Warren M and Carvey PM (2008). Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant, 17: 363-372
14. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM and Schlossmacher MG (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol, 213: 315-325
15. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M and El-Agnaf OM (2010). Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75:1766-1772
16. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG and El-Agnaf OM (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun, 349:162-166
17. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D and Zhang J (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol, 69: 570-580
18. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P and El-Agnaf O (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord, 26: 1428-1435
19. Puschmann A (2013). Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord, 19: 407-415
20. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB and Zhang J (2010). Significance and confounders of peripheral DJ--synuclein in Parkinson's disease. Neurosci Lett, 480: 78-82
21. Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ and Shi M and Zhang J (2012). DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep, 2: 954
22. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T and Hashimoto M (2006). Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun, 345: 967-972
23. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH and Zhang J (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133: 713-726
24. Del Tredici K, Hawkes CH, Ghebremedhin E and Braak H (2010). Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol, 119: 703-713
25. Niranjan R (2013). The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol, epub ahead of print.
26. Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R and Ferrarese C (2006). Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis, 23: 36-43
27. Prigione A, Isaias IU, Galbussera A, Brighina L, Begni B, Andreoni S, Pezzoli G, Antonini A and Ferrarese C (2009). Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Parkinsonism Relat Disord, 15: 327-328
28. Migliore L, Petrozzi L, Lucetti C, Gambaccini G, Bernardini S, Scarpato R, Trippi F, Barale R, Frenzilli G, Rodilla V and Bonuccelli U (2002). Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology, 58: 1809-1815
29. Sato S, Mizuno Y and Hattori N (2005). Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology, 64: 1081-1083
30. Werner CJ, Heyny-von Haussen R, Mall G and Wolf S (2008). Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci, 6: 8
31. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M and Chazot G (2007). Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol, 58: 78-83
32. Korff A, Pfeiffer B, Smeyne M, Kocak M, Pfeiffer RF and Smeyne RJ (2011). Alterations in glutathione S-transferase pi expression following exposure to MPP+ -induced oxidative stress in the blood of Parkinson's disease patients. Parkinsonism Relat Disord, 17: 765-768
33. Church WH and Ward VL (1994). Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull, 33: 419-425
34. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA and Ascherio A (2008). Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol, 167: 831-838
35. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA and Parkinson Study Group DATATOP Investigators (2006). Urate as a predictor of the rate of clinical decline in Parkinson disease Arch Neurol, 66: 1460-1468
36. Cheng FC, Kuo JS, Chia LG and Dryhurst G (1996). Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm, 103: 433-446
37. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Arch Neurol 1995, 52: 237-245
38. LeWitt P, Schultz L, Auinger P, Lu M and Parkinson Study Group DATATOP Investigators (2011). CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res, 1408: 88-97
39. Kitsou E, Pan S, Zhang J, Shi M, Zabeti A, Dickson DW, Albin R, Gearing M, Kashima DT, Wang Y, Beyer RP, Zhou Y, Pan C, Caudle WM and Zhang J (2008). Identification of proteins in human substantia nigra. Proteomics Clin Appl, 2: 776-782
40. Mila S, Albo AG, Corpillo D, Giraudo S, Zibetti M, Bucci EM, Lopiano L and Fasano M (2009). Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomark Med, 3: 117-128
41. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H and Trojanowski JQ (2011). Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol, 69: 655-663
42. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ and Zhang J (2006). Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293-348
43. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG and Montine TJ (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol, 129: 526-529
44. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS and Flint Beal M (2008). Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain, 131: 389-396
45. Ahmed SS, Santosh W, Kumar S and Christlet HT (2009). Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci, 16: 63
46. Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF and Bogdanov M (2009). Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One, 4: e7551
47. Smith DJ (2009). Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics. J Bioenerg Biomembr, 41:487-491
48. Caudle WM, Bammler TK, Lin Y, Pan S and Zhang J (2010). Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother, 10: 925-942
49. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV and Gullans SR (2007). Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A, 104: 955-960
50. Shadrina MI, Filatova EV, Karabanov AV, Slominsky PA, Illarioshkin SN, Ivanova-Smolenskaya IA and Limborska SA (2010). Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease. Neurosci Lett, 473: 257-259